A phase III, open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies

Overview of attention for article published in Journal of Inherited Metabolic Disease, October 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#10 of 2,553)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 11 news outlets
policy: 1 policy source

twitter: 7 X users

Readers on

mendeley: 26 Mendeley

So far, Altmetric has seen 9 X posts from 7 X users, with an upper bound of 11,109 followers.

RT @JIMD_Editors: Adding to a recent glut of #fabry papers we’ve another one, this time with a focus on ERT and there’s another #visualabst…

In the course of Fabry disease, there is an increasing reduction in glomerular filtration rate (GFR) of up to 10–12ml/min/year. This tends to be the case even with enzyme replacement therapy. If the $SGMO gene therapy actually shows improved eGFR values, …

RT @JIMD_Editors: Adding to a recent glut of #fabry papers we’ve another one, this time with a focus on ERT and there’s another #visualabst…

A phase 3 open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease https://t.co/zZumnmG4eg Treatment burden and adherence are always an issue with ERT. A one-time gene therapy would be a leap forw…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 5 additional X posts.